Neurodome Secures Tens of Millions in Series A Funding to Advance Temporal Interference Technology in Brain Science

Recently, Neurodome, Inc. (hereinafter referred to as "Neurodome") successfully completed a multi-million yuan Series A financing round. This round of financing will help the company accelerate the ongoing exploration and development of Temporal Interference (TI) technology in the field of brain science, promote multi-scenario product solutions, and advance clinical registration, product certification, and commercialization for various indications.

Neurodome, Inc., founded in 2019 and based in Xi'an, specializes in the field of non-invasive neuromodulation. Continuously refining TI technology, Neurodome was the first to master and achieve precise non-invasive deep-brain neuromodulation in humans using TI. The company's TI products can accurately output various stimulation signal patterns and finely adjust parameters according to clinical needs, ensuring the accuracy, effectiveness, and repeatability of treatment protocols. These products enable perfect non-invasive, deep-brain, high-precision, multi-target stimulation and intervention of the central nervous system, with broad applications in the treatment of various neurological and psychiatric disorders.

The field of brain science holds immense potential for therapeutic needs. In China, the number of patients with various brain diseases is close to 130 million, including over 50 million with depression. The burden caused by brain diseases accounts for 23% of the total disease burden. Current treatment methods have many shortcomings, struggling to balance safety and efficacy. Invasive treatments carry high risks, while non-invasive interventions struggle to achieve both depth and precision. This challenging yet fascinating blue ocean track urgently calls for a new technology leader that can simultaneously meet the clinical demands of being non-invasive, deep-brain, precise, and multi-targeted.

Neurodome, Inc. has established a comprehensive product portfolio, achieving full coverage of scenarios from research to clinical settings and from in-hospital to out-of-hospital environments, with its research products already commercially available. Recently, Neurodome, Inc. unveiled new product solutions, TI – TMS and TI-TUS, integrating innovative technologies to provide novel tools and technical solutions for clinical research and applications.
In September 2024, the first Global TI Summit, International Meeting on Temporal Interference Brain Stimulation, grandly opened in London. As an industry-leading enterprise, Neurodome showcased its significant breakthroughs in TI technology development, clinical applications, and product innovation to global clinical and research professionals in the TI field. Alongside top neuroscientists, medical experts, and industry leaders worldwide, Neurodome discussed the future development of TI technology in the field of neuromodulation.

Marching forward with courage and perseverance, committed to our mission. In the future, Neurodome will continue to drive innovation, iterate around TI technology, focus on deep brain modulation, and launch a multi-physical factor modulation product line covering the functional cortex and central-peripheral nervous system, building a globally leading non-invasive deep brain neuromodulation platform based on TI stimulation.